CAPTRUST Financial Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

CAPTRUST Financial Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-621	Closed	-$5K	–	4226
2022 Q2	$5K	Buy	621 +221	+55%	+$1.77K	﹤0.01%	4132
2022 Q1	$4K	Hold	400	–	–	﹤0.01%	4292
2021 Q4	$3K	Hold	400	–	–	﹤0.01%	4318
2021 Q3	$4K	Hold	400	–	–	﹤0.01%	4063
2021 Q2	$4K	Buy	+400	New	+$4.45K	﹤0.01%	3974

Other funds holding LUMO

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

CAPTRUST Financial Advisors's LUMO Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q3 2022, closing a stake of 621 shares — an estimated $5K sold.

CAPTRUST Financial Advisors first reported a position in LUMO in Q2 2021 and held it in 5 quarters. The position peaked at $5K in Q2 2022. 35 funds tracked by Wall St. Rank hold LUMO as of Q3 2022.

CAPTRUST Financial Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
CAPTRUST Financial Advisors sold 621 Lumos Pharma, Inc. Common Stock shares in Q3 2022, an estimated $5K.
CAPTRUST Financial Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
CAPTRUST Financial Advisors's Lumos Pharma, Inc. Common Stock position peaked at $5K in Q2 2022.
35 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.